Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result

Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result

<strong>Background:</strong> Blood biomarkers may aid in recruitment to clinical trials of Alzheimer’s disease (AD) modifying therapeutics by triaging potential trials participants for amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests. <strong&g...

Description complète

Détails bibliographiques
Auteurs principaux:	Westwood, S, Baird, AL, Hye, A, Ashton, NJ, Nevado-Holgado, AJ, Anand, SN, Liu, B, Newby, D, Bazenet, C, Kiddle, SJ, Ward, M, Newton, B, Desai, K, Hehir, C, Zanette, M, Galimberti, D, Parnetti, L, Lleó, A, Baker, S, Narayan, VA, Van Der Flier, WM, Scheltens, P, Teunissen, CE, Visser, PJ, Lovestone, S
Format:	Journal article
Publié:	Frontiers Media 2018

Documents similaires

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result
par: Sarah Westwood, et autres
Publié: (2018-12-01)

The influence of insulin resistance on CSF and plasma biomarkers of Alzheimer’s pathology
par: Westwood, S, et autres
Publié: (2017)

New CSF biomarkers on the block
par: Charlotte E Teunissen, et autres
Publié: (2016-09-01)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
par: Rosha Babapour Mofrad, et autres
Publié: (2019-12-01)

Determining the molecular pathways underlying the protective effect of non-steroidal anti-inflammatory drugs for Alzheimer's disease: A bioinformatics approach
par: Nevado-Holgado, A, et autres
Publié: (2016)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
par: Eleonora M. Vromen, et autres
Publié: (2022-01-01)

Blood-based proteomic biomarkers of Alzheimer’s disease pathology
par: Baird, A, et autres
Publié: (2015)

Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach
par: Alejo J Nevado-Holgado, et autres
Publié: (2017-01-01)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
par: Betty Marije Tijms, et autres
Publié: (2021-08-01)

Establishing cutoff values for visual amyloid positivity in [18F]flutemetamol PET
par: Yong-Jin Park, et autres
Publié: (2025-01-01)

Amyloid-Targeting PET Tracer [18F]Flutemetamol Accumulates in Atherosclerotic Plaques
par: Sanna Hellberg, et autres
Publié: (2019-03-01)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
par: Teunissen, C, et autres
Publié: (2018)

Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
par: Lyduine E. Collij, et autres
Publié: (2023-11-01)

Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET
par: Si Eun Kim, et autres
Publié: (2020-01-01)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
par: Eline A. J. Willemse, et autres
Publié: (2021-01-01)

Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice.
par: Stephanie J B Vos, et autres
Publié: (2014-01-01)

Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study
par: Yanaika S. Hok‐A‐Hin, et autres
Publié: (2023-07-01)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer's disease
par: Winchester, L, et autres
Publié: (2018)

Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods
par: Mark R. Battle, et autres
Publié: (2018-12-01)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
par: Charlotte E. Teunissen, et autres
Publié: (2018-03-01)

Binary classification of ¹⁸F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI.
par: Vandenberghe, R, et autres
Publié: (2013)

Early-phase 18F-FP-CIT and 18F-flutemetamol PET were significantly correlated
par: Young-Sil An, et autres
Publié: (2021-06-01)

Temporal and anatomical distribution of 18F-flutemetamol uptake in canine brain using positron emission tomography
par: Taesik Yun, et autres
Publié: (2020-01-01)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
par: Juhan Reimand, et autres
Publié: (2019-12-01)

Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly
par: Westwood, S, et autres
Publié: (2016)

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.
par: Vandenberghe, R, et autres
Publié: (2010)

Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment
par: Hugh G. Pemberton, et autres
Publié: (2023-05-01)

Automatic lesion detection and segmentation in 18F-flutemetamol positron emission tomography images using deep learning
par: Chan Ju Ryu
Publié: (2022-12-01)

Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
par: Fiona Heeman, et autres
Publié: (2019-03-01)

Cross-sectional and longitudinal analyses of outdoor air pollution exposure and cognitive function in UK Biobank
par: Cullen, B, et autres
Publié: (2018)

Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank
par: Nevado-Holgado, A, et autres
Publié: (2016)

Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and CSF
par: Winchester, L, et autres
Publié: (2022)

18F-flutemetamol PET/CT imaging in the diagnosis of mild cognitive impairment and Alzheimer's disease：a preliminary study
par: LEI Zhe, et autres
Publié: (2022-07-01)

Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques
par: Milos D. Ikonomovic, et autres
Publié: (2018-06-01)

Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study
par: Hiroshi Matsuda, et autres
Publié: (2021-01-01)

Blood based proteomic biomarkers of Alzheimer’s disease pathology
par: Alison Louise Baird, et autres
Publié: (2015-11-01)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
par: Carla M. Startin, et autres
Publié: (2019-03-01)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer’s disease
par: Laura M. Winchester, et autres
Publié: (2018-06-01)

Synaptic protein CSF levels relate to memory scores in individuals without dementia
par: Wesenhagen, KEJ, et autres
Publié: (2025)

Synaptic protein CSF levels relate to memory scores in individuals without dementia
par: Kirsten E. J. Wesenhagen, et autres
Publié: (2025-03-01)